Filing Summary
Entity and period: The supplied filing is a Form 10-Q for Marika Inc., a Nevada development-stage company, for the quarter ended September 30, 2014—not a filing for Palvella Therapeutics, Inc. The financial statements are unaudited. Marika reported no business operations; it had planned to offer online errand and concierge services.
Financial Results and Liquidity
- Revenue: $0 for the quarter, compared with $0 in the prior-year quarter.
- Loss: Net loss was $13,918, versus $5,762 a year earlier. Professional fees were $13,900, compared with $5,750; other operating expenses were $18, compared with $12. Basic and diluted loss per share was reported as $0.00, rounded.
- Cash and assets: Cash and total assets were $220 at September 30, down from $11,138 at June 30, 2014.
- Liabilities and equity: Current liabilities were $1,124, comprising $650 accounts payable and a $474 unsecured, non-interest-bearing director loan due on demand. Stockholders’ equity was a deficit of $904, down from positive equity of $10,014 at June 30.
- Cash flow: Operating cash use was $13,918; financing provided $3,000 from a common-stock sale. The cash-flow statement reports ending cash of $220.
- Capitalization: The company issued 150,000 shares for $3,000 during the quarter. It reported 6,250,000 shares outstanding at September 30 and November 13, 2014.
Changes, Outlook, and Risks
- The quarterly net loss increased by $8,156 year over year, primarily alongside higher professional fees. The company continued to report no revenue.
- Management said existing funds and anticipated financing were expected to cover operations for the next three months, but stated that additional funding would be needed within the next 12 months. It expected to seek equity financing and possibly director loans; no future financing arrangements were in place. Equity or convertible-debt issuance could dilute shareholders, and financing might not be available on acceptable terms.
- The filing states that the auditor’s review report included an explanatory paragraph expressing substantial doubt about the company’s ability to continue as a going concern. Management also acknowledged limited working capital and dependence on additional capital.
- Management concluded disclosure controls and procedures were not effective as of September 30, 2014. It reported no material change in internal control over financial reporting during the quarter.
- The company reported no material subsequent events through October 21, 2014 and no known pending or threatened legal proceedings. It reported no material off-balance-sheet arrangements.
Investor Verification Points
- Confirm the issuer identity: the supplied filing names Marika Inc., while the request identifies Palvella Therapeutics, Inc.
- Reconcile the cash-flow statement: operating cash use of $13,918 plus financing cash of $3,000 implies a $10,918 decrease, but the statement labels the net increase as positive $10,918; beginning cash of $11,138 and ending cash of $220 imply a decrease.
- Verify the director-loan balance and history: the notes describe loans totaling $874, while the reported outstanding balance is $474.
- Assess near-term financing needs, going-concern uncertainty, and the effectiveness of disclosure controls.